Israel Newsletter News Roundup 6/18/2007

Written by: Zack Miller | June 18, 2007

Zack Miller

www.IsraelNewsletter.com 

Optibase (OBAS) wins Huawei deal to provide advanced MPEG-4/H.264 encoding and streaming as part of their IPTV offering. No details on size of the bid but good Tier-1 approbation.

Elbit (ESLT) continues on its string of small wins with a new win announced today. The $14MM deal is to supply the Aviator’s Night Vision Imaging System/Head-Up Displays for helicopters of two NATO member countries.

York Capital, an $8 Billion NY-based hedge fund, has been all over the local press following their 2006 purchase of Psagot Ofek Investment House. Globes now reports that they’ve made a $2.7MM investment in NetManage (NETM), run by CEO and Chairman, Zvi Alon. NetManage markets software for integrating, web enabling, and accessing enterprise information systems. The company currently has a market cap of about $46 million. It ended the first quarter of 2007 with sales of $7.7 million and a loss of $3.6 million.

Interesting Frost & Sullivan report out saying that Israel’s biomed industry is growing quickly.   The report cites that 80% of current biomedical companies functioning in Israel were funded only within the past 10 years.  “This can be seen in the huge number of patents registered in Israel, the largest number of patents per capita in world for medical devices, and the fourth largest number in biopharmaceuticals. Israel is one of the top 20 countries in spending per capita in the field,” said the report.

Disclosure: Author’s fund is long ESLT 6/18/07.

Please see our Disclaimer HERE.

Like what you see? Sign up to receive daily updates from IsraelNewsletter here.

**************

Zack Miller is the lead equity analyst for America Israel Investment Associates, LLC. and a former equity analyst for a leading multinational hedge fund. For more information, go to www.israelnewsletter.com or call 1-888-327-6179, or email zack@profile-financial.com

Related posts

Category: Uncategorized

No Comments »

No comments yet.

Leave a comment